{"id":23478,"date":"2021-04-21T00:00:00","date_gmt":"2021-04-21T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/2021\/04\/21\/response-to-first-vaccination-against-sars-cov-2-in-patients-with-multiple-myeloma-en-anglais\/"},"modified":"2021-04-21T00:00:00","modified_gmt":"2021-04-21T05:00:00","slug":"response-to-first-vaccination-against-sars-cov-2-in-patients-with-multiple-myeloma-en-anglais","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2021\/04\/21\/response-to-first-vaccination-against-sars-cov-2-in-patients-with-multiple-myeloma-en-anglais\/","title":{"rendered":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma (en anglais)"},"content":{"rendered":"<p><em>Multiple myeloma is a malignancy of plasma cells, which is highly associated with immune suppression. Consistent with this, reports of outcomes of COVID-19 infection in patients with multiple myeloma show higher rates of severe disease than in the general population.<\/em><\/p>\n<p>Cliquez <a href=\"https:\/\/www.thelancet.com\/action\/showPdf?pii=S2352-3026%2821%2900110-1\" target=\"_blank\" rel=\"noopener\"><strong>ici<\/strong><\/a> pour lire la suite (en anglais).<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Multiple myeloma is a malignancy of plasma cells, which is highly associated with immune suppression. Consistent with this, reports of outcomes of COVID-19 infection in patients with multiple myeloma show higher rates of severe disease than in the general population. Cliquez ici pour lire la suite (en anglais). &nbsp; &nbsp;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[72],"tags":[],"class_list":["post-23478","post","type-post","status-publish","format-standard","hentry","category-actualites-et-nouvelles-au-sujet-de-la-covid-19"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/23478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=23478"}],"version-history":[{"count":0,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/23478\/revisions"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=23478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=23478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=23478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}